Vnitřní lékařství 8/2020

PŘEHLEDOVÉ ČLÁNKY Věkem podmíněná remodelace myokardu:mýtus nebo realita? | 511  / Vnitř Lék 2020; 66(8): 507–511  /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz sledovaných ukazatelů měli pacienti s vlohami pro nižší LDL cholesterol (OR 0,73, 95% CI: 0,70–0,75; p < 0,001), pak následovali pacienti s vlohami pouze pro nižší krevní tlak (OR 0,82, 95% CI: 0,79–0,85, p < 0,001). Studie prokázala významdélky expozice rizikovým faktorůmna osud nemocných a významaktivního pátrání po rizikovémprofilu nemocných (například na základě tabulek SCORE) a včasné korekce (35, 36). Závěr Věkem podmíněná remodelace myokardu je dlouhodobý proces, který zahrnuje široké spektrumpatogenetickýchmechanismů. Výsledkem jsou strukturální a funkční změny, které mohou ústit v rozvoj srdečního selhání, snižovat kvalitu života a zvyšovat tak morbiditu i mortalitu pa‑ cientů. Jde o proces, který mohou negativně ovlivnit rizikové faktory kardiovaskulárních onemocnění, řada komorbidit, naopak tento proces lze významně pozitivně ovlivnit změnou životního stylu, včasnou detekcí rizikových faktorů a důslednou léčbou komorbidit. Podpořeno grantemAZVMZ ČR NV19-02-00297 a institucionální podpo- rou Lékařské fakulty Univerzity Karlovy v Hradci Králové Progres Q 40/03. LITERATURA 1. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Vartiainen E, Sans S, Paster‑ kamp G, Hughes M, Costanzo S, Donati MB, Jousilahti P, Linneberg A, Palosaari T, de Gaetano G, Bobak M, den Ruijter HM, Jorgensen T, Soderberg S, Kuulasmaa K, Zeller T, Iacoviello L, Salo‑ maa V, Schnabel RB, BiomarCa REC. Sex‑Specific Epidemiology of Heart Failure Risk and Mor‑ tality in Europe: Results From the BiomarCaRE Consortium. JACCHeart Fail. 2019; 7(3): 204–213. 2. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Bur‑ den of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289(2): 194–202. 3. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age‑related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi­ ‑Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2009; (3): 191–198. 4. Fiechter M, Fuchs TA, Gebhard C, Stehli J, Klaeser B, Stahli BE, Manka R, Manes C, Tanner FC, Gaemperli O, Kaufmann PA. Age‑related normal structural and functional ventricular values in cardiac function assessed by magnetic resonance. BMC Med Imaging. 2013; 13:6. 5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez­ ‑Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribu‑ tion of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200. 6. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3 rd , Dokainish H, Edvardsen T, Flachskam‑ pf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Alexandru Popescu B, Waggo‑ ner AD, Houston T, Oslo N, Phoenix A, Nashville T, Hamilton OC, Uppsala S, Ghent, Liege B, Cleveland O, Novara I, Rochester M, Bucharest R, St. Louis M. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovas‑ cular Imaging. Eur Heart J Cardiovasc Imaging. 2016; 17(12): 1321–1360. 7. Evin M, Redheuil A, Soulat G, Perdrix L, Ashrafpoor G, Giron A, Lamy J, Defrance C, Roux C, Hatem SN, Diebold B, Mousseaux E, Kachenoura N. Left atrial aging: a cardiac magnetic resonance feature‑tracking study. Am J Physiol Heart Circ Physiol. 2016; 310(5): H542–549. 8. Jalife J, Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015; 25(6): 475–484. 9. Wehrum T, Lodemann T, Hagenlocher P, Stuplich J, Ngo BTT, Grundmann S, Hennemuth A, Hennig J, Harloff A. Age‑related changes of right atrial morphology and inflow pattern assessed using 4D flow cardiovascular magnetic resonance: results of a population‑based study. J Cardiovasc Magn Reson. 2018; 20(1): 38. 10. Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart. 2016; 102(11): 825–831. 11. Christou DD, Seals Dr. Decreased maximal heart rate with aging is related to reduced {beta}-adrenergic responsiveness but is largely explained by a reduction in intrinsic he‑ art rate. J Appl Physiol (1985). 2008; 105(1): 24–29. 12. Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Andersen MJ, Dahl JS, Hassager C, Mo‑ ller JE, Gustafsson F. The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals. JACC Heart Fail. 2017; 5(5): 337–346. 13. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, Wu TD, Guerquin­ ‑Kern JL, Lechene CP, Lee RT. Mammalian heart renewal by pre‑existing cardiomyocytes. Nature. 2013 Jan; 493(7432): 433–436. 14. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe‑Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J. Evidence for cardiomyocyte renewal in humans. Science. 2009; 324(5923): 98–102. 15. Bergmann O, Zdunek S, Felker A, Salehpour M, Alkass K, Bernard S, Sjostrom SL, Szewc‑ zykowska M, Jackowska T, Dos Remedios C, Malm T, Andra M, Jashari R, Nyengaard JR, Po‑ ssnert G, Jovinge S, Druid H, Frisen J. Dynamics of Cell Generation and Turnover in the Human Heart. Cell. 2015; 161(7): 1566–1575. 16. Li H, Hastings MH, Rhee J, Trager LE, Roh JD, Rosenzweig A. Targeting Age‑Related Pathways in Heart Failure. Circ Res. 2020; 126(4): 533–551. 17. Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, Mingoia JT, Sweterlitsch SE, Spinale FG. Age‑dependent changes in myocardial matrix metalloproteinase/tissue inhibi‑ tor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005; 66(2): 410–419. 18. Triposkiadis F, Xanthopoulos A, Parissis J, Butler J, Farmakis D. Pathogenesis of chro‑ nic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev. 2020 Jun 10. 19. Gonzalez‑Lopez E, Gallego‑Delgado M, Guzzo‑Merello G, de Haro‑Del Moral FJ, Cobo­ ‑Marcos M, Robles C, Bornstein B, Salas C, Lara‑Pezzi E, Alonso‑Pulpon L, Garcia‑Pavia P. Wild‑type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36(38): 2585–2594. 20. Vaclavik J. Blood vessel ageing and vascular memory. Vnitr Lek. 2020; 66(2): 104–110. 21. Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failu‑ re: Contemporary Update. JACC Heart Fail. 2017; 5(8): 543–551. 22. López‑Sainz A dH‑DMJ, Dominguez F, Restrepo‑Cordoba A, Amor‑Salamanca A, Hernandez‑Hernandez A, Ruiz‑Guerrero L, Krsnik I, Cobo‑Marcos M. Prevalence of cardi‑ ac amyloidosis among elderly patients with systolic heart failure or conduction disorde‑ rs. Amyloid. 2019; 26: 156–136. 23. Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74(6): 804–813. 24. Tousoulis D, Oikonomou E, Siasos G, Stefanadis C. Diabetes Mellitus and Heart Failu‑ re. Eur Cardiol. 2014; 9(1): 37–42. 25. Seals DR, Brunt VE, Rossman MJ. Keynote lecture: strategies for optimal cardiovascu‑ lar aging. Am J Physiol Heart Circ Physiol. 2018; 315(2): H183–H188. 26. Seals DR, Brunt VE, Rossman MJ. Keynote lecture: strategies for optimal cardiovascu‑ lar aging. 2018; 315(2): H183–H188. 27. Woo JS, Derleth C, Stratton JR, Levy WC. The influence of age, gender, and training on exercise efficiency. J Am Coll Cardiol. 2006; 47(5): 1049–1057. 28. Roh J, Rhee J, Chaudhari V, Rosenzweig A. The Role of Exercise in Cardiac Aging: From Physiology to Molecular Mechanisms. Circ Res. 2016; 118(2): 279–295. 29. Fujimoto N, Prasad A, Hastings JL, Arbab‑Zadeh A, Bhella PS, Shibata S, Palmer D, Levine BD. Cardiovascular effects of 1 year of progressive and vigorous exercise trai‑ ning in previously sedentary individuals older than 65 years of age. Circulation. 2010; 122(18): 1797–1805. 30. Werner C, Hanhoun M, Widmann T, Kazakov A, Semenov A, Poss J, Bauersachs J, Thum T, Pfreundschuh M, Muller P, Haendeler J, Bohm M, Laufs U. Effects of physical exercise on myocardial telomere‑regulating proteins, survival pathways, and apoptosis. J Am Coll Car‑ diol. 2008; 52(6): 470–482. 31. Werner C, Furster T, Widmann T, Poss J, Roggia C, Hanhoun M, Scharhag J, Buchner N, Meyer T, Kindermann W, Haendeler J, Bohm M, Laufs U. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation. 2009; 120(24): 2438–2447. 32. Liao PH, Hsieh DJ, Kuo CH, Day CH, Shen CY, Lai CH, Chen RJ, Padma VV, Kuo WW, Huang CY. Moderate exercise training attenuates aging‑induced cardiac inflammation, hypertro‑ phy and fibrosis injuries of rat hearts. Oncotarget. 2015; 6(34): 35383–35394. 33. Vujic A, Lerchenmuller C, Wu TD, Guillermier C, Rabolli CP, Gonzalez E, Senyo SE, Liu X, Guerquin‑Kern JL, Steinhauser ML, Lee RT, Rosenzweig A. Exercise induces new car‑ diomyocyte generation in the adult mammalian heart. Nat Commun. 2018; 9(1): 1659. 34. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Ni‑ cholls SJ, Sabatine MS. Association of Genetic Variants Related to Combined Exposure to Lower Low‑Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322: 1381–1391. 35. Ray KK, Laufs U, Cosentino F, Lobo MD, Landmesser U. The year in cardiology: cardio‑ vascular prevention. Eur Heart J. 2020; 41(11): 1157–1163. 36. Lim GB. Reductions in LDL‑cholesterol and blood‑pressure levels have cumulative be‑ nefits. Nat Rev Cardiol. 2019; 16(11): 650.